Emirates Haematology Conference 2026

Dr. Ah Hassan recently completed his Internal Medicine residency training and obtained the Saudi Board certification in Hematology. He is building his clinical career with a strong foundation in diagnosing and managing hematologic disorders, with a growing interest in advancing patient care and contributing to the field through continuous learning and professional development.

Dr. Ahmad Alabdulkarim is a Specialist Haematologist at Jaber Alahmad Hospital, Kuwait. He earned his MD from the Royal College of Surgeons in Ireland and is board-certified by the Kuwait Board of Haematology. Dr. Alabdulkarim completed a Clinical Fellowship in Myeloproliferative Neoplasms and Myelodysplastic Syndromes at University College London Hospital and serves as a Clinical Tutor at the Kuwait Institute of Medical Specialisations, contributing to patient care and medical education.

Professor Ahmad M. Tarawah is a pediatric hematologist and oncologist based in Madinah, Saudi Arabia. He serves as a consultant at King Salman Medical City and chairs the Madinah Hereditary Blood Disorders Society. Holding a medical degree from King Abdulaziz University (1990), he completed pediatric training in Edinburgh and earned his Arab Board certification in 1997. He further specialized in pediatric hematology/oncology at King Faisal Specialist Hospital, obtaining a fellowship in 2001. Professor Tarawah has authored over 140 publications, contributed to national treatment guidelines, and founded multiple hematology societies and charitable organizations. His work focuses on hemophilia, sickle cell anemia, and bleeding disorders.

Dr. Ahmed Alaskar is a consultant hematologist and academic leader with extensive expertise in adult hematology and stem cell transplantation. He serves as Executive Director of the King Abdullah International Medical Research Center (KAIMRC) and is a professor at King Saud bin Abdulaziz University for Health Sciences. His work focuses on clinical research, biotechnology development, and advancing hematology practice, with active contributions to international publications and scientific collaborations.

Dr. Ajlan Al Zaki, MD, PhD, is a consultant hematologist-oncologist and physician-scientist at Cleveland Clinic Abu Dhabi. He specializes in hematologic malignancies and advanced cellular therapies, with a strong focus on translational research. Dr. Al Zaki trained at MD Anderson Cancer Center and Stanford University, and has authored numerous peer-reviewed publications and patents. His work centers on advancing innovative cancer therapies and improving patient access to cutting-edge treatments in the region.

Ali T. Taher, MD, PhD, FRCP is Professor of Medicine at the American University of Beirut (AUB), Director of the Naef K. Basile Cancer Institute, and Associate Vice President for Academic Centers and External Affairs. He is an internationally recognized leader in thalassemia and iron metabolism, with major contributions to prevention and clinical care in Lebanon and beyond. Dr. Taher has authored more than 540 peer-reviewed publications (h-index 84; over 32,000 citations) and has led landmark international clinical trials, including a Phase 3 study of oral mitapivat published in The Lancet. His achievements have been recognized with numerous prestigious awards, including the National Cedar Medal of Lebanon, the Sultan Bin Khalifa International Thalassemia Award, and the EHA Education and Mentoring Award. He currently chairs the EHA Scientific Working Group on Red Cells and Iron and serves on scientific committees of the American Society of Hematology (ASH).

Dr Amal Al Haddad is the Operations Director Administrator at Shaikh Shakhbout Medical City – Abu Dhabi. Dr Amal has over 17 years of experience serving various clinical, managerial, academic and research roles at multiple government and private institutions within UAE including; SKMC & Tawam Hospitals, the College of Medicine at the UAE University, Al Noor Hospital Group/Mediclinic Middle East, Moorfields Eye Hospital, & other various facilities and academic institutions. She is also the former Vice President of the American College of Health Care Executives (ACHE) – MENA. Dr. Amal obtained her PhD from the UAE University; Master of Business and Management from the University of Wollongong- Dubai; and her nursing degrees from Abu Dhabi institute of nursing and Sharjah University. She has a diploma in hematology and an advanced training in palliative and end-of-life care. She is a recognized subject matter expert, a trainer and a speaker at many national and international conferences. She is also a member in ASCO, ONS, POEM, SIOP and ACHE. In addition, she won various scholarship, research grants, and research awards. Dr Al Haddad also has multiple ongoing research projects and peer-reviewed publications.

Dr. Amar Lal is a senior Consultant in Hematology and Oncology with over 30 years of distinguished clinical and academic experience. Internationally credentialed with triple fellowships from CPSP, triple memberships of the Royal Colleges of Physicians, and ESMO certification, he has authored more than 50 peer-reviewed publications and is a respected global speaker. At Tawam Hospital, he plays a key leadership role in advancing oncology excellence and patient safety.

Dr. Amna Al Mehairi is a Consultant Hematologist at Dubai Health with extensive expertise in hematology and the management of blood cancers. She also serves as an Adjunct Clinical Professor of Medicine, contributing to medical education and training. Dr. Al Mehairi is committed to advancing patient care through clinical excellence, academic involvement, and continuous professional development in the field of hematology.

Dr. Ashraf Warsi is a Consultant in Adult Hematology at Princess Noura Oncology Center, King Abdulaziz Medical City, Jeddah, Ministry of National Guard–Health Affairs, Western Region, Saudi Arabia. He is American Board–certified in Internal Medicine and Adult Hematology and certified by the Royal College of Physicians and Surgeons of Canada. He completed a Clinical Thrombosis Fellowship at McGill University, Montreal. His special interests include thrombosis, bleeding disorders, and myeloproliferative neoplasms.

Asma is the Acting Nurse Manager at Tawam Hospital, with a wide range of expertise in the hematology, oncology and palliative, also had position of Hematology/oncology navigator which has supported her experience with patients. She is the winner of Daisy Award and SEHA IHSAN Award, ENA member and trainee in RCSI SEHA program. Moderator in International Medical Conferences, Instructor in Oncology Educational Program and member of Oncology Nursing Advisory Group at SEHA.

Dr. Asma Al Olama is the President of the Emirates Society of Haematology and a Consultant Hematologist at Dubai Hospital. She has been actively involved in the field of hematology, particularly in the UAE, and has contributed to various initiatives and best practices in the area. Additionally, she serves as the Program Director of the Adult Hematology Fellowship program at Dubai Health.

Asst Prof Dr. Faraz Khan is a Consultant Hematologist and Medical Oncologist with over 15 years experience in treating cancer and various blood diseases. He completed his Internal Medicine, Hematology and Medical oncology training from the University of Connecticut, CT, USA and is triple board certified in Internal medicine, Hematology and Medical Oncology. He worked as a consultant Hematologist/Medical Oncologist at PEI Cancer Treatment Center, PE, Canada and directed the provincial hemophilia and bleeding disorder clinic.

Dr. Hadeel Mahmmoud Ammar is a Consultant in Internal Medicine, Hematology, and Pathology at Dubai Hospital, Dubai Health Authority (DHA). With over 23 years of clinical experience, she specializes in managing complex hematologic and systemic disorders. Dr. Ammar earned her MBBS from Dubai Medical College and completed her Arab Board certification with training in Syria. She is known for her patient-centered, evidence-based approach and plays an active role in clinical education and multidisciplinary care initiatives across the UAE.

Dr. Hani Yousif Osman is a UK-trained consultant physician in medicine, hematology, and oncology at Tawam Hospital. He specializes in the diagnosis and treatment of hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, as well as benign blood and bleeding disorders. A graduate of University of Khartoum, he completed advanced training in the United Kingdom and has published research in his field.

Hanny Al-Samkari, M.D. is a classical hematologist and leading international clinical investigator in hemostasis, platelet disorders, and hemolytic anemias. His focus is on the development of novel therapeutics in hereditary hemorrhagic telangiectasia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia and hemolytic anemia. He serves as global principal investigator for many ongoing studies in these areas.

Dr. Hasan Al Yaseen is a Consultant in Internal Medicine and Hematology with extensive clinical experience in the United Arab Emirates. He holds an MBBS degree from Baghdad University and has over three decades of practice in diagnosing and managing complex hematologic and internal medicine conditions. Dr. Yaseen is actively involved in advancing evidence based patient care and contributes to regional clinical research in hematology.

Dr. Hateeti has extended experience in Haematology, Oncology, and Internal Medicine, having worked for more than 25 years in the field. He was a lead physician in Haematology at Shiekh Khalifa Medical City (SKMC) for more than a decade and currently, he is a lead physician in lymphoma and benign Haematology at Sheikh Shakhbout Medical City. In addition, Dr. Hateeti was a principal investigator and co-investigator in international multi-centre medical trials and has papers published in regional medical journals. He has a special interest in lymphoma and rare haematology disorders; HLH, PNH, TTP/HUS, haematologic storage disorders like Gaucher disease, beta-thalassemia, and other hemoglobinopathies.

Dr. El-Najjar is an astute practitioner and researcher with 20 years of extensive experience in both the UAE and the UK. She has held several prominent positions exemplifying her commitment to the highest standards of clinical excellence, including working as a Consultant Hematologist at the prestigious Guy’s and St. Thomas NHS trust in central London. Additionally, she served as an Honorary Consultant at King’s College London Moreover, she has published several papers in peer-reviewed journals and presented at prominent international meetings, including the American Society of Hematology and the European Bone Marrow Transplant. As a further demonstration of her leadership capabilities, she served as the Lead Educational Supervisor for hematology core medical trainees at Guy's Hospital in partnership with the London Deanery. Dr. El-Najjar strives to provide patients with evidence-based hematology care in accordance with the latest research.

Dr. Jasmine M. Zain, MD, is a board‑certified hematologist‑oncologist and attending physician at Memorial Sloan Kettering Cancer Center in New York and New Jersey, specializing in the diagnosis and management of lymphomas, particularly T‑cell and cutaneous T‑cell lymphomas. Her expertise encompasses CAR T‑cell therapy, chemotherapy, immunotherapy, and stem cell transplantation. With decades of experience, she leads clinical care and research, including novel conditioning regimens and cellular therapies for rare lymphomas.

Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center, and Associate Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson's clinical and research interests are in non-Hodgkin lymphomas, Hodgkin lymphoma, and CLL. His research involves identifying the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases.

Dr. Jesús San-Miguel, MD, PhD, is a Professor of Medicine-Hematology and Director of Clinical and Translational Medicine at the University of Navarra, Spain. Formerly, he led the Hematology Department at the University Hospital of Salamanca for over 20 years and served as President of the International Myeloma Society (2012–2019). A pioneer in multiple myeloma research, he has published over 900 papers, with major contributions to myeloma biology, minimal residual disease, and the development of novel therapies. He holds numerous national and international honors and serves on multiple advisory boards and editorial committees.

Mr. Khaled is currently a Unit Manager within the Pediatric Hematology-Oncology Unit at the Tawam Hospital, United Arab Emirates. Khaled began his academic journey with a Bachelor of Science in Nursing from the University of Jordan in Amman, establishing a strong clinical foundation. Driven by his passion for leadership and healthcare excellence, he advanced his studies in the United States, earning a Master of Science in Healthcare Administration from the University of Atlanta. To further expand his expertise on an international scale, he recently completed a second master’s degree in Global Child Health from St. Jude Academy in the United States, solidifying his global vision and commitment to advancing Pediatric care worldwide. He actively participates in many Haemophilia -focused groups, taking on the role of Nurses Committee Member for the World Federation of Haemophilia (WFH), and General Secretary and Haemophilia Nurse at the United Arab Emirates Haemophilia Group. Khaled is also the Chairperson for the Nursing Care Working Group initiated by the Pediatric Oncology Eastern Mediterranean (POEM) Group, which aims to continuously improve Pediatric oncology care, research, training and advocacy in the eastern and Mediterranean region by means of integrated teamwork. Khaled a leadership consultant for the development of health services and medical personnel at the Arab Leadership and Foresight Agency which aims to improve health care in Low and Middle Income Countries (LMICs).

Khaled Al Qawasmeh, RN, MSN, APRN, OCNS, CCRP, is a Clinical Research Nurse and Senior Clinical Nurse Specialist in Oncology and Hematology at Tawam Hospital’s Oncology Department. He brings extensive expertise in oncology nursing, clinical research, and evidence-based practice, with a strong focus on improving patient outcomes and advancing cancer care. Khaled holds a Master’s degree in Clinical Oncology Nursing from the University of Pennsylvania. He has been an Oncology Certified Nurse (OCN) since 2009 and is also a Certified Clinical Research Professional through the Society of Clinical Research Associates. In addition, he serves as Chair of the SEHA SOCRA Chapter, supporting research excellence and professional development. He is the Chair of the SEHA Nursing Research and Evidence-Based Practice Committee, where he leads initiatives that promote the integration of research into clinical nursing practice. Khaled also serves as Vice President of the Emirates Oncology Hematology Nursing Society, contributing to the advancement of oncology and hematology nursing at a national level. Through his leadership and dedication, Khaled continues to strengthen the role of research-driven, patient-centered care within oncology nursing.

Dr. Khalil Al Farsi is a Senior Consultant in Hematology and Bone Marrow Transplantation at the National Center for Hematology and BMT, University Medical City, Sultan Qaboos University, Muscat, Oman. His clinical expertise includes lymphoma, multiple myeloma, and autologous stem cell transplantation.

Dr. Khawla M. Belhoul is a highly experienced Consultant in Internal Medicine and Hematology with more than 25 years of clinical practice in the UAE. She is a Fellow of the Royal College of Physicians (UK) and trained in hematology at Imperial College School of Medicine, London. Dr. Belhoul has played key roles in general hematology and benign blood disorders, including hemoglobinopathies, and has participated in international clinical trials and publications. She has been a featured speaker at regional and international medical conferences, contributing to advancements in hematology care and research.

Mahmoud Hasan is the Chief Nursing Officer at Al Dhafra Hospitals - SEHA, where he oversees the nursing staff and ensures the highest standards of patient care. With over 23 years of experience in the healthcare industry, Mahmoud brings a wealth of knowledge and a passion for nursing excellence to the role. Mahmoud earned his Master of Science in healthcare management from the Royal College of Surgeons in Ireland (RCSI). He began his career as a registered nurse in in oncology and BMT services, quickly rising through the ranks due to his dedication, clinical expertise, and leadership skills. Mahmoud Led the oncology nursing services at Tawam Hospital as Assistant Director of Nursing. Throughout his career, Mahmoud has been instrumental in implementing patient-centred care models, improving nursing workflows, and enhancing patient safety protocols. He is known for his collaborative approach, working closely with multidisciplinary teams to foster a culture of continuous improvement and innovation. At Al Dhafra Hospitals - SEHA, Mahmoud is responsible for strategic planning, policy development, and the overall management of nursing services. He is committed to nurturing a supportive and empowering environment for all nursing staff, promoting ongoing education, professional development, and evidence-based practice. Mahmoud participated in number of oncology nursing research such as improving oral chemotherapy compliance in Oncology Clinic, improving patient experience with Chemotherapy-induced nausea and vomiting (CINV), Tawam Experience and Assessing the Patient Education needs of Thalassemia Patients taking Iron chelating factors, Experience of Tawam hospital adult hematology/oncology department in the UAE.

Prof. Mahmoud Marashi is a Consultant Haematologist at Mediclinic City Hospital with over 30 years of experience. He established the clinical haematology service in Dubai Health Authority, managing both benign (anemias, bleeding disorders, thrombosis) and malignant (leukemias, myeloma, myeloproliferative disorders) hematologic conditions. A Professor of Medicine and Haematology, he leads undergraduate and postgraduate haematology training at Dubai Medical College, serves as Head of the Academic Department of Medicine, and is an external examiner for the Royal College of Physicians, UK.

Dr. Mark Levis is a graduate of the Medical Scientist Training Program from U.C. San Francisco and completed clinical training at Johns Hopkins University. He is a Professor of Oncology and the Director of the Adult Leukemia Service at Johns Hopkins. His clinical expertise focuses on acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. His research goals are to identify and validate novel molecular therapeutic targets in AML.

Dr. Litzow is a Professor of Hematology at Mayo Clinic. He has served as Director of the BMT Program and the Acute Leukemia Group at Mayo Clinic. He served as chair of the Leukemia Committee of the ECOG-ACRIN Group from 2013 to 2022. He was a co-chair of the Acute Leukemia Working Committee of the CIBMTR. He served on the Board of Directors for the Foundation for the Accreditation of Cellular Therapy for 9 years. He is the author of over 700 manuscripts.

Dr. Marwa Ahmed is a board-certified hematologist and internist, certified by the Saudi Commission for Health Specialties (SCFHS).

Dr Marwan Shaheen is the Head of Chronic Leukemia and Myeloproliferative Neoplasms Section in the Department of Hematology, SCT and Cellular Therapy at King Faisal Specialist Hospital and Research Centre- Riyadh. He is also the Director of Long Term Follow-up program in Cancer Centre of Excellence. Dr Shaheen is certified Saudi Board of Internal Medicine and Adult Hematology then completed a fellowship in Adult Hematology and Bone Marrow Transplant at Princess Margaret Cancer Centre in Toronto, Canada. He was also the first certified Stem Cell Transplant Fellow from KFSH&RC.

Dr. Maysar Hussam Ahmed AbuEbaid is a Hematology Fellow in Dubai, UAE, with a strong background in internal medicine. She completed her residency at Mohammed Bin Rashid University and earned her MBBS with distinction from the University of Sharjah. With frontline COVID-19 experience and a 2025 publication in respiratory care, she is passionate about evidence-based medicine, research, and improving patient outcomes through collaborative clinical practice.

Dr. Mohamed Abuhaleeqa is an esteemed Consultant in Hematology, Leukemia, and Bone Marrow Transplant. With a robust medical journey that includes qualifications from prestigious institutions and a specialization in Hematology, he is a dedicated healthcare leader. Dr. Abuhaleeqa's commitment to knowledge sharing is evident through his mentoring of junior doctors and his role as the Program Director for the Hematology Fellowship Program in the UAE. His extensive qualifications include FRCPSC in Leukemia and Bone Marrow Transplant, Hematology, and Internal Medicine, and he is registered with the College of Physicians and Surgeons of British Columbia. He is an active participant in seminars, symposiums, and research in hematology and a member of respected medical associations, including ASBMT, EBMT and CIBMTR, underscoring his dedication to healthcare advancement in the UAE.

Dr. Mozah Obaid Almarshoodi is a Consultant in Benign Hematology and the Acting Head of Medical Department at Sheikh Khalifa Hospital Fujairah, specializing in blood disorders, including thrombosis, bleeding disorders, and hemoglobinopathies. She completed her Consultative Hematology Fellowship at the University of Toronto and is skilled in patient care, education, and clinical research. Fluent in Arabic and English, Dr. Almarshoodi is dedicated to improving hematology care and mentoring future medical professionals in the UAE.

Prof. Mubarak Al-Mansour is a Senior Medical Oncologist at King’s College Hospital London in Jeddah and Chairman of Adult Medical Oncology at Princess Noorah Oncology Center. With over 16 years of experience, he specializes in lymphoma and genitourinary cancers. He completed his training at the University of British Columbia and holds American and Canadian board certifications in Internal Medicine and Medical Oncology. Prof. Al-Mansour is an active academic at King Saud bin Abdulaziz University for Health Sciences and a leading contributor to oncology research, with multiple publications in lymphoma and solid tumors.

Dr. Muna Altarshi is a Senior Consultant at the Royal Hospital, Muscat. She earned her MD from Sultan Qaboos University and completed Internal Medicine and Hematology training at McGill University, obtaining FRCPC and American Board certifications. She completed a Bone Marrow Transplant fellowship at Princess Margaret Cancer Centre, University of Toronto. Her practice focuses on lymphoma, plasma cell myeloma, and autologous stem cell transplantation. She is Associate Program Director at the Oman Medical Specialty Board and Treasurer of the Omani Society of Hematology.

Prof. Murtadha Al-Khabori is a Professor of Hematology at Sultan Qaboos University and Senior Consultant Hematologist at Sultan Qaboos University Hospital, Oman. He leads the Hematology Department and plays a key role in the national bone marrow transplant program. He completed advanced hematology and stem cell transplant training at Princess Margaret Hospital and research training at McMaster University, Canada. Prof. Al-Khabori has authored over 100 peer-reviewed publications and serves as an Associate Editor of the Oman Medical Journal. His clinical and research interests focus on acute leukemia, myeloproliferative neoplasms, and hematopoietic stem cell transplantation.

Dr. Naseema Gangat is a Professor of Medicine with the Division of Hematology at the Mayo Clinic, Rochester, MN. She currently serves as the Education Chair, Division of Hematology and program director for the advanced hematology fellowship program. Her clinical and research interests are focused on myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). She has authored/co-authored over a hundred papers and key contributions to the field include improving prognostication, investigating the connection between mutations and clinical phenotype, and evaluating novel therapeutics. Dr Gangat served as editor in chief of the American Society of Hematology News Daily (2021-2022), associate editor of the American Society of Hematology Clinical News (2023-2025) and is currently an Associate editor for Blood Cancer Journal.

Dr. Panayotis Kaloyannidis is a Specialist Hematologist at Burjeel Medical City with over 25 years of experience in malignant hematology and cellular therapies. He has participated in more than 2,000 hematopoietic stem cell transplants, including autologous and allogeneic procedures. His expertise includes leukemia, lymphoma, stem cell transplantation, post-transplant complications, and advanced cellular therapies such as CAR T-cell therapy and immunotherapy for hematologic malignancies.

Dr. Seliem did her Anatomic and Clinical pathology Residency in Baystate Medical Center, Tufts University, USA after doing two years of research in Columbia University in St. Luke’s –Roosevelt hospital in New York City. She then joined Massachusetts general Hospital, Harvard Medical School as a Senior/Chief resident in Anatomic and Clinical pathology then completed both Surgical Pathology and Hematopathology Fellowships in the same institution. She successfully obtained the American Board in Anatomic/ Clinical pathology and Hematology in 2005 and 2006. She joined the Pathology and laboratory medicine department in Dubai Health Authority as a Hematopathology consultant and has been appointed as the chair of Rashid Hospital Pathology Department and hematology unit since December 2006. Dr. Rania has several publications in the field of hematology, especially neoplastic Hematopathology. She is the chair of several scientific committees and the scientific chair of the Emirates Society of Hematology (ESH) since 2012. She also hold an academic position in Dubai Medical College as an associate professor. Her main areas of interest are Neoplastic Hematopathology and Flow cytometry and she is especially interested in improving the health care practices and quality standards in the United Arab Emirates.

Dr. Ranjana Advani is a Professor of Medicine at Stanford University specializing in the field of lymphoma. She holds an endowed chair (Saul Rosenberg Professor) and oversees all aspects of treatment of the vast majority of adult lymphoma patients. Her primary research interests include improving care for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients by optimizing front line regimens, developing novel agents and targeted therapy for refractory and recurrent disease, advancing correlative studies involving biomarkers, and addressing long-term outcomes. She leads multi-institutional efforts as a national study Principal Investigator (PI) or Co-PI on several targeted therapies, translational and imaging studies and has published extensively in the peer reviewed literature. She is a member of the NCCN guidelines committee for Hodgkin Lymphoma (Chair) and Non-Hodgkin Lymphoma and on the lymphoma core committee for the Eastern Cooperative Oncology Group. She has also served as a voting member of the ODAC (Oncology Drug Advisory Committee) to the FDA, and has completed a term as the co-chair of the National Cancer Institute Lymphoma Steering Committee.

Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.

Dr. Ruba Taha is a Consultant in Clinical Hematology at NCCCR-HMC, specializing in benign and malignant hematological disorders and stem cell transplantation. She serves as Clinical Lead of Lymphoma and Chair of the Lymphoma MDT since 2014, and is an active member of leukemia and BMT multidisciplinary teams. Dr. Taha is also a principal investigator on multiple research grants and contributes to national clinical and academic committees.

Prof. Salam Salim Alkindi is a Professor and Consultant Hematologist, at the Department of Haematology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman. Prior to that, Dr. Alkindi served as the head of Hematology Department, Sultan Qaboos University Hospital, Oman. In 2002, he was a visiting physician, at the Transplant Unit, University of Washington, Medical Centre, Seattle - WA, USA. He has over 80 publications in several international peer-reviewed journals. His research interests include; hemoglobinopathies, leukemia, sickle cell disease, stem cell transplant, regulatory B cells in hemophilia patients, inherited von Willebrand disease, pulmonary hypertension in sickle cell disease patients, and chronic lymphocytic leukemia.

Dr. Salem H. D. Al-Shemmari is a hematologist-oncologist and academic at Kuwait University with extensive expertise in malignant hematology and stem cell transplantation. Trained in Canada and at the Fred Hutchinson Cancer Research Center, he has led major clinical and research initiatives, including establishing oncology fellowship programs and a myeloid neoplasm reference lab. He has authored over 60 publications and continues to advance hematology through research, teaching, and clinical leadership.

Dr. Sarah Sewaralthahab is a hematologist and medical oncologist trained in the United States, currently serving as Assistant Professor of Medicine at King Saud University. She specializes in malignant and benign hematologic disorders, including lymphoma, leukemia, anemia, and thrombosis. With a special interest in obstetric hematology and women’s health, she is committed to delivering compassionate, evidence-based care and improving patient outcomes through clinical excellence and academic engagement.

Dr. Somaya Al Nuaimi is a Pediatric Consultant and Head of the Thalassemia Department at Fujairah Hospital, with over 20 years of clinical experience. She led the department to recognition as a Center of Excellence and is an Associate Professor at Ras Al Khaimah Medical University. Holding MRCPCH and Arab Board certification, she is an active educator, speaker, and certified trainer, contributing extensively to pediatric care and professional development in the UAE.

Dr. Sumaya is the President of Emirates Nursing Association, Director of Nursing Department in Emirates Health Services, Leading the National Nursing & Midwifery Strategy in the UAE and Honorary associate professor at MBRU. Leading the taskforce committee for Cabinet Initiative (Attractiveness of Nursing Profession). Dr. Sumaya is an Awardee of Emirates Pride Medal for Mohammed Bin Rashid Government 2017; Community serving Medal 2020; Best Government Communication Campaign in promoting nursing profession (2018). “Pioneer Nurse” at the Global Health Pioneer Awards. She is recently inducted as fellow of American Academy of Nursing.

Valeria Santini is an Associate Professor of Hematology at the University of Florence Medical School in Florence Italy, where she received her degree in Medicine and Postgraduate diploma in hematology (cum laude). She worked as an EORTC fellow in experimental hematology from 1988 to 1991 at the Dr. den Hoed Kliniek, Erasmus University, Rotterdam. In 1999 she worked in the Department of Leukemia at MD Anderson Cancer Center, University of Texas, Houston. Her scientific interests and publications are focused on maturation induction and therapeutic targeting of epigenetics modifications, myeloid leukemias and myelodysplastic syndromes (MDS). At present Dr. Santini is responsible for the MDS and chronic myeloid leukemia (CML) program of the Hematology Unit at the University of Florence. She is a member of European Hematology Association (EHA), MDS Foundation, Italian Society of Experimental Hematology. Dr. Santini is a member of the Executive Board of the Italian Society of Hematology and the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation.

Dr. AI-Shaibani completed his clinical fellowship in Allogeneic Transplantation within the Hans Messner Allogenic Transplant Program, Canada as well as additional fellowship training in both the Leukemia and Lymphoma Programs at the Princess Margaret Cancer Centre. In 2018, Dr. Al-Shaibani completed the Master Teacher Program at the University of Toronto. Dr. Al-Shaibani is appointed as an Assistant Professor in the Department of Medicine, University of Toronto.